U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry RACEMIC
Molecular Formula C12H24N2O4
Molecular Weight 260.33
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CARISOPRODOL

SMILES

CCCC(C)(COC(N)=O)COC(=O)NC(C)C

InChI

InChIKey=OFZCIYFFPZCNJE-UHFFFAOYSA-N
InChI=1S/C12H24N2O4/c1-5-6-12(4,7-17-10(13)15)8-18-11(16)14-9(2)3/h9H,5-8H2,1-4H3,(H2,13,15)(H,14,16)

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including: http://www.ncbi.nlm.nih.gov/pubmed/22318620, http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7c9184c0-7a2e-11df-8c8d-0002a5d5c51b

A centrally acting skeletal muscle relaxant whose mechanism of action is not completely understood but may be related to its sedative actions. Carisoprodol is indicated for the relief of discomfort associated with acute, painful musculoskeletal conditions in adults. Most common adverse reactions (incidence > 2%) are drowsiness, dizziness, and headache. Carisoprodol might be mixtured with Aspirin and Codeine Phosphate. Studies indicating increased risk of abuse or addiction led to withdrawal of the drug from the market in Norway and other EU countries in 2008.

Originator

Curator's Comment: Carisoprodol was developed in the 1950s by Dr. Frank M. Berger at Wallace laboratories on the basis of meprobamate.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
142.0 µM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
SOMA

Approved Use

SOMA is indicated for the relief of discomfort associated with acute, painful musculoskeletal conditions in adults. SOMA should only be used for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use has not been established and because acute, painful musculoskeletal conditions are generally of short duration

Launch Date

1959
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
13.3 μM
700 mg single, oral
dose: 700 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CARISOPRODOL serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1.2 μg/mL
250 mg single, oral
dose: 250 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CARISOPRODOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
1.8 μg/mL
350 mg single, oral
dose: 350 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CARISOPRODOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
4.5 μg × h/mL
250 mg single, oral
dose: 250 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CARISOPRODOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
7 μg × h/mL
350 mg single, oral
dose: 350 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CARISOPRODOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
99 min
700 mg single, oral
dose: 700 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CARISOPRODOL serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1.7 h
250 mg single, oral
dose: 250 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CARISOPRODOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
2 h
350 mg single, oral
dose: 350 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CARISOPRODOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
46%
700 mg single, oral
dose: 700 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CARISOPRODOL serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
250 mg 3 times / day steady, oral
Recommended
Dose: 250 mg, 3 times / day
Route: oral
Route: steady
Dose: 250 mg, 3 times / day
Sources:
unhealthy, 41 years
Health Status: unhealthy
Age Group: 41 years
Sex: M+F
Sources:
Disc. AE: Dizziness, Headache...
AEs leading to
discontinuation/dose reduction:
Dizziness (0.5%)
Headache (0.5%)
Diarrhea (0.2%)
Stomach discomfort (0.2%)
Upper abdominal pain (0.2%)
Intervertebral disc protrusion (0.2%)
Pain in extremity (0.2%)
Abdominal distension (0.2%)
Sources:
350 mg 3 times / day steady, oral
Recommended
Dose: 350 mg, 3 times / day
Route: oral
Route: steady
Dose: 350 mg, 3 times / day
Sources:
unhealthy, 41 years
Health Status: unhealthy
Age Group: 41 years
Sex: M+F
Sources:
Disc. AE: Dizziness, Headache...
AEs leading to
discontinuation/dose reduction:
Dizziness (0.7%)
Headache (0.4%)
Stomach discomfort (0.7%)
Upper abdominal pain (0.7%)
Somnolence (0.7%)
Nausea (0.4%)
Rash (0.4%)
Nephrolithiasis (0.4%)
Intervertebral disc protrusion (0.4%)
Fatigue (0.4%)
Disorientation (0.4%)
Paraesthesia (0.4%)
Skin papilloma (0.4%)
Sources:
2100 mg 1 times / day steady, oral
Highest studied dose
Dose: 2100 mg, 1 times / day
Route: oral
Route: steady
Dose: 2100 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M
Sources:
AEs

AEs

AESignificanceDosePopulation
Abdominal distension 0.2%
Disc. AE
250 mg 3 times / day steady, oral
Recommended
Dose: 250 mg, 3 times / day
Route: oral
Route: steady
Dose: 250 mg, 3 times / day
Sources:
unhealthy, 41 years
Health Status: unhealthy
Age Group: 41 years
Sex: M+F
Sources:
Diarrhea 0.2%
Disc. AE
250 mg 3 times / day steady, oral
Recommended
Dose: 250 mg, 3 times / day
Route: oral
Route: steady
Dose: 250 mg, 3 times / day
Sources:
unhealthy, 41 years
Health Status: unhealthy
Age Group: 41 years
Sex: M+F
Sources:
Intervertebral disc protrusion 0.2%
Disc. AE
250 mg 3 times / day steady, oral
Recommended
Dose: 250 mg, 3 times / day
Route: oral
Route: steady
Dose: 250 mg, 3 times / day
Sources:
unhealthy, 41 years
Health Status: unhealthy
Age Group: 41 years
Sex: M+F
Sources:
Pain in extremity 0.2%
Disc. AE
250 mg 3 times / day steady, oral
Recommended
Dose: 250 mg, 3 times / day
Route: oral
Route: steady
Dose: 250 mg, 3 times / day
Sources:
unhealthy, 41 years
Health Status: unhealthy
Age Group: 41 years
Sex: M+F
Sources:
Stomach discomfort 0.2%
Disc. AE
250 mg 3 times / day steady, oral
Recommended
Dose: 250 mg, 3 times / day
Route: oral
Route: steady
Dose: 250 mg, 3 times / day
Sources:
unhealthy, 41 years
Health Status: unhealthy
Age Group: 41 years
Sex: M+F
Sources:
Upper abdominal pain 0.2%
Disc. AE
250 mg 3 times / day steady, oral
Recommended
Dose: 250 mg, 3 times / day
Route: oral
Route: steady
Dose: 250 mg, 3 times / day
Sources:
unhealthy, 41 years
Health Status: unhealthy
Age Group: 41 years
Sex: M+F
Sources:
Dizziness 0.5%
Disc. AE
250 mg 3 times / day steady, oral
Recommended
Dose: 250 mg, 3 times / day
Route: oral
Route: steady
Dose: 250 mg, 3 times / day
Sources:
unhealthy, 41 years
Health Status: unhealthy
Age Group: 41 years
Sex: M+F
Sources:
Headache 0.5%
Disc. AE
250 mg 3 times / day steady, oral
Recommended
Dose: 250 mg, 3 times / day
Route: oral
Route: steady
Dose: 250 mg, 3 times / day
Sources:
unhealthy, 41 years
Health Status: unhealthy
Age Group: 41 years
Sex: M+F
Sources:
Disorientation 0.4%
Disc. AE
350 mg 3 times / day steady, oral
Recommended
Dose: 350 mg, 3 times / day
Route: oral
Route: steady
Dose: 350 mg, 3 times / day
Sources:
unhealthy, 41 years
Health Status: unhealthy
Age Group: 41 years
Sex: M+F
Sources:
Fatigue 0.4%
Disc. AE
350 mg 3 times / day steady, oral
Recommended
Dose: 350 mg, 3 times / day
Route: oral
Route: steady
Dose: 350 mg, 3 times / day
Sources:
unhealthy, 41 years
Health Status: unhealthy
Age Group: 41 years
Sex: M+F
Sources:
Headache 0.4%
Disc. AE
350 mg 3 times / day steady, oral
Recommended
Dose: 350 mg, 3 times / day
Route: oral
Route: steady
Dose: 350 mg, 3 times / day
Sources:
unhealthy, 41 years
Health Status: unhealthy
Age Group: 41 years
Sex: M+F
Sources:
Intervertebral disc protrusion 0.4%
Disc. AE
350 mg 3 times / day steady, oral
Recommended
Dose: 350 mg, 3 times / day
Route: oral
Route: steady
Dose: 350 mg, 3 times / day
Sources:
unhealthy, 41 years
Health Status: unhealthy
Age Group: 41 years
Sex: M+F
Sources:
Nausea 0.4%
Disc. AE
350 mg 3 times / day steady, oral
Recommended
Dose: 350 mg, 3 times / day
Route: oral
Route: steady
Dose: 350 mg, 3 times / day
Sources:
unhealthy, 41 years
Health Status: unhealthy
Age Group: 41 years
Sex: M+F
Sources:
Nephrolithiasis 0.4%
Disc. AE
350 mg 3 times / day steady, oral
Recommended
Dose: 350 mg, 3 times / day
Route: oral
Route: steady
Dose: 350 mg, 3 times / day
Sources:
unhealthy, 41 years
Health Status: unhealthy
Age Group: 41 years
Sex: M+F
Sources:
Paraesthesia 0.4%
Disc. AE
350 mg 3 times / day steady, oral
Recommended
Dose: 350 mg, 3 times / day
Route: oral
Route: steady
Dose: 350 mg, 3 times / day
Sources:
unhealthy, 41 years
Health Status: unhealthy
Age Group: 41 years
Sex: M+F
Sources:
Rash 0.4%
Disc. AE
350 mg 3 times / day steady, oral
Recommended
Dose: 350 mg, 3 times / day
Route: oral
Route: steady
Dose: 350 mg, 3 times / day
Sources:
unhealthy, 41 years
Health Status: unhealthy
Age Group: 41 years
Sex: M+F
Sources:
Skin papilloma 0.4%
Disc. AE
350 mg 3 times / day steady, oral
Recommended
Dose: 350 mg, 3 times / day
Route: oral
Route: steady
Dose: 350 mg, 3 times / day
Sources:
unhealthy, 41 years
Health Status: unhealthy
Age Group: 41 years
Sex: M+F
Sources:
Dizziness 0.7%
Disc. AE
350 mg 3 times / day steady, oral
Recommended
Dose: 350 mg, 3 times / day
Route: oral
Route: steady
Dose: 350 mg, 3 times / day
Sources:
unhealthy, 41 years
Health Status: unhealthy
Age Group: 41 years
Sex: M+F
Sources:
Somnolence 0.7%
Disc. AE
350 mg 3 times / day steady, oral
Recommended
Dose: 350 mg, 3 times / day
Route: oral
Route: steady
Dose: 350 mg, 3 times / day
Sources:
unhealthy, 41 years
Health Status: unhealthy
Age Group: 41 years
Sex: M+F
Sources:
Stomach discomfort 0.7%
Disc. AE
350 mg 3 times / day steady, oral
Recommended
Dose: 350 mg, 3 times / day
Route: oral
Route: steady
Dose: 350 mg, 3 times / day
Sources:
unhealthy, 41 years
Health Status: unhealthy
Age Group: 41 years
Sex: M+F
Sources:
Upper abdominal pain 0.7%
Disc. AE
350 mg 3 times / day steady, oral
Recommended
Dose: 350 mg, 3 times / day
Route: oral
Route: steady
Dose: 350 mg, 3 times / day
Sources:
unhealthy, 41 years
Health Status: unhealthy
Age Group: 41 years
Sex: M+F
Sources:
Overview

Overview

OverviewOther

Other InhibitorOther SubstrateOther Inducer



Drug as perpetrator​Drug as victim
PubMed

PubMed

TitleDatePubMed
WHO Expert Committee on Drug Dependence. Thirty-second report.
2001
Abuse of combinations of carisoprodol and tramadol.
2001 May
[Guidelines concerning acute low back pain].
2002 Apr 30
Urticaria to carisoprodol.
2002 Jan
[Carisoprodol--one more time].
2002 Jan 30
Carisoprodol: an unrecognized drug of abuse.
2002 Mar
Somatic dysfunction during carisoprodol cessation: evidence for a carisoprodol withdrawal syndrome.
2003 Feb
Association between blood carisoprodol:meprobamate concentration ratios and CYP2C19 genotype in carisoprodol-drugged drivers: decreased metabolic capacity in heterozygous CYP2C19*1/CYP2C19*2 subjects?
2003 Jul
Possible dangerous interaction of oxycontin and carisoprodol.
2003 Jun 1
Possible dangerous interaction of oxycontin and carisoprodol.
2003 Mar 1
A near-fatal overdose of carisoprodol (SOMA): case report.
2004
Tolerance and dependence risk with the use of carisoprodol.
2004 Apr 1
Validated semiquantitative/quantitative screening of 51 drugs in whole blood as silylated derivatives by gas chromatography-selected ion monitoring mass spectrometry and gas chromatography electron capture detection.
2004 Jul 5
Fatal intoxications in a Swedish forensic autopsy material during 1992-2002.
2004 Jun 30
Commonly used muscle relaxant therapies for acute low back pain: a review of carisoprodol, cyclobenzaprine hydrochloride, and metaxalone.
2004 Sep
The CYP2C19 genotype and the use of oral contraceptives influence the pharmacokinetics of carisoprodol in healthy human subjects.
2005 Aug
Human pharmaceuticals, hormones, and personal care product ingredients in runoff from agricultural fields irrigated with treated wastewater.
2005 Mar 9
Treatment of carisoprodol dependence: a case report.
2005 Sep
Carisoprodol abuse in Texas, 1998-2003.
2006 Mar
Carisoprodol abuse in Mississippi.
2007 Dec
Is the frequency of carisoprodol withdrawal syndrome increasing?
2007 Oct
Acute intoxications with carisoprodol.
2008 Apr
Reliability of Ashworth and Modified Ashworth scales in children with spastic cerebral palsy.
2008 Apr 10
Is it time for carisoprodol to become a controlled substance at the federal level?
2008 Feb
Double-blind, placebo-controlled trial of carisoprodol 250-mg tablets in the treatment of acute lower-back spasm.
2008 Feb
Muscle and reflex changes with varying joint angle in hemiparetic stroke.
2008 Feb 27
Carisoprodol-induced amnestic state.
2008 Jan
[Toxicological screening of medicines and drugs of abuse in emergency cases].
2008 Jan 3
Carisoprodol withdrawal syndrome misdiagnosed as a psychotic disorder.
2008 Jul-Sep
Drug screening of hair by liquid chromatography-tandem mass spectrometry.
2008 Jun
Analysis of pain management drugs, specifically fentanyl, in hair: application to forensic specimens.
2008 Mar 21
Carisoprodol should be taken off the market.
2008 Oct
Novel transcriptional profile in wrist muscles from cerebral palsy patients.
2009 Jul 14
Quantitative analysis of carisoprodol and meprobamate in whole blood using benzylcarbamate and deuterated meprobamate as internal standards.
2009 Jun
Fibromyalgia and myofascial pain syndrome-a dilemma.
2009 Oct
Drugs associated with more suicidal ideations are also associated with more suicide attempts.
2009 Oct 2
Regulation of intermittent oscillatory activity of pyramidal cell neurons by GABA inhibitory interneurons is impaired in schizophrenia: rationale for pharmacotherapeutic GABAergic interventions.
2010
Carisoprodol legal status and patterns of abuse.
2010 Dec
Pharmacogenetics and forensic toxicology.
2010 Dec 15
INCITE: A randomised trial comparing constraint induced movement therapy and bimanual training in children with congenital hemiplegia.
2010 Jan 12
Trace determination of pharmaceuticals and other wastewater-derived micropollutants by solid phase extraction and gas chromatography/mass spectrometry.
2010 Jan 22
Carisoprodol withdrawal after internet purchase.
2010 Jul
Pharmaceutical formulation facilities as sources of opioids and other pharmaceuticals to wastewater treatment plant effluents.
2010 Jul 1
The relation between neuromechanical parameters and Ashworth score in stroke patients.
2010 Jul 27
Adaptive robot training for the treatment of incoordination in Multiple Sclerosis.
2010 Jul 29
Observations of medication compliance by measurement of urinary drug concentrations in a pain management population.
2010 Jul-Aug
Pharmacologic management of chronic pain.
2010 Jun
Quantification of the effects of an alpha-2 adrenergic agonist on reflex properties in spinal cord injury using a system identification technique.
2010 Jun 23
Comparison of drug concentrations in blood and oral fluid collected with the Intercept sampling device.
2010 May
Screening and quantitative determination of twelve acidic and neutral pharmaceuticals in whole blood by liquid-liquid extraction and liquid chromatography-tandem mass spectrometry.
2010 Sep
Patents

Sample Use Guides

250 mg to 350 mg three times a day and at bedtime
Route of Administration: Oral
In Vitro Use Guide
HEK293 cells were transiently transfected with human alpha1beta2 and alpha1beta2gamma2 receptors. Whole-cell patch clamp electrophysiology was used to assess carisoprodol-activated Cl- current. EC50 value for carisoprodol was 142 ± 13 uM.
Name Type Language
CARISOPRODOL CIV
USP-RS  
Preferred Name English
CARISOPRODOL
EP   HSDB   INN   JAN   MART.   MI   ORANGE BOOK   USP   VANDF   WHO-DD  
INN  
Official Name English
(±)-2-METHYL-2-PROPYL-1,3-PROPANEDIOL CARBAMATE ISOPROPYLCARBAMATE
Systematic Name English
CARISOPRODOL [HSDB]
Common Name English
CARISOPRODOL [USP MONOGRAPH]
Common Name English
NSC-172124
Code English
CARISOPRODOL [MI]
Common Name English
CARISOPRODOL [EP IMPURITY]
Common Name English
CARISOPRODOL [JAN]
Common Name English
carisoprodol [INN]
Common Name English
SOMA
Brand Name English
Carisoprodol [WHO-DD]
Common Name English
RELA
Brand Name English
SOMA COMPOUND COMPONENT CARISOPRODOL
Common Name English
CARISOPRODOL [VANDF]
Common Name English
CARISOPRODOL [ORANGE BOOK]
Common Name English
CARISOPRODOL CIV [USP-RS]
Common Name English
CARISOPRODOL COMPOUND COMPONENT CARISOPRODOL
Common Name English
CARISOPRODOL [MART.]
Common Name English
Classification Tree Code System Code
NDF-RT N0000175737
Created by admin on Mon Mar 31 17:45:36 GMT 2025 , Edited by admin on Mon Mar 31 17:45:36 GMT 2025
LIVERTOX NBK548829
Created by admin on Mon Mar 31 17:45:36 GMT 2025 , Edited by admin on Mon Mar 31 17:45:36 GMT 2025
WHO-ATC M03BA72
Created by admin on Mon Mar 31 17:45:36 GMT 2025 , Edited by admin on Mon Mar 31 17:45:36 GMT 2025
WHO-VATC QM03BA72
Created by admin on Mon Mar 31 17:45:36 GMT 2025 , Edited by admin on Mon Mar 31 17:45:36 GMT 2025
WHO-VATC QM03BA52
Created by admin on Mon Mar 31 17:45:36 GMT 2025 , Edited by admin on Mon Mar 31 17:45:36 GMT 2025
WHO-ATC M03BA02
Created by admin on Mon Mar 31 17:45:36 GMT 2025 , Edited by admin on Mon Mar 31 17:45:36 GMT 2025
NCI_THESAURUS C29696
Created by admin on Mon Mar 31 17:45:36 GMT 2025 , Edited by admin on Mon Mar 31 17:45:36 GMT 2025
WHO-VATC QM03BA02
Created by admin on Mon Mar 31 17:45:36 GMT 2025 , Edited by admin on Mon Mar 31 17:45:36 GMT 2025
DEA NO. 8192
Created by admin on Mon Mar 31 17:45:36 GMT 2025 , Edited by admin on Mon Mar 31 17:45:36 GMT 2025
WHO-ATC M03BA52
Created by admin on Mon Mar 31 17:45:36 GMT 2025 , Edited by admin on Mon Mar 31 17:45:36 GMT 2025
NDF-RT N0000175730
Created by admin on Mon Mar 31 17:45:36 GMT 2025 , Edited by admin on Mon Mar 31 17:45:36 GMT 2025
Code System Code Type Description
NCI_THESAURUS
C28904
Created by admin on Mon Mar 31 17:45:36 GMT 2025 , Edited by admin on Mon Mar 31 17:45:36 GMT 2025
PRIMARY
MESH
D002328
Created by admin on Mon Mar 31 17:45:36 GMT 2025 , Edited by admin on Mon Mar 31 17:45:36 GMT 2025
PRIMARY
SMS_ID
100000084595
Created by admin on Mon Mar 31 17:45:36 GMT 2025 , Edited by admin on Mon Mar 31 17:45:36 GMT 2025
PRIMARY
RS_ITEM_NUM
1096600
Created by admin on Mon Mar 31 17:45:36 GMT 2025 , Edited by admin on Mon Mar 31 17:45:36 GMT 2025
PRIMARY
WIKIPEDIA
CARISOPRODOL
Created by admin on Mon Mar 31 17:45:36 GMT 2025 , Edited by admin on Mon Mar 31 17:45:36 GMT 2025
PRIMARY
LACTMED
Carisoprodol
Created by admin on Mon Mar 31 17:45:36 GMT 2025 , Edited by admin on Mon Mar 31 17:45:36 GMT 2025
PRIMARY
FDA UNII
21925K482H
Created by admin on Mon Mar 31 17:45:36 GMT 2025 , Edited by admin on Mon Mar 31 17:45:36 GMT 2025
PRIMARY
DAILYMED
21925K482H
Created by admin on Mon Mar 31 17:45:36 GMT 2025 , Edited by admin on Mon Mar 31 17:45:36 GMT 2025
PRIMARY
CHEBI
3419
Created by admin on Mon Mar 31 17:45:36 GMT 2025 , Edited by admin on Mon Mar 31 17:45:36 GMT 2025
PRIMARY
IUPHAR
7610
Created by admin on Mon Mar 31 17:45:36 GMT 2025 , Edited by admin on Mon Mar 31 17:45:36 GMT 2025
PRIMARY
HSDB
3021
Created by admin on Mon Mar 31 17:45:36 GMT 2025 , Edited by admin on Mon Mar 31 17:45:36 GMT 2025
PRIMARY
DRUG BANK
DB00395
Created by admin on Mon Mar 31 17:45:36 GMT 2025 , Edited by admin on Mon Mar 31 17:45:36 GMT 2025
PRIMARY
EPA CompTox
DTXSID8024733
Created by admin on Mon Mar 31 17:45:36 GMT 2025 , Edited by admin on Mon Mar 31 17:45:36 GMT 2025
PRIMARY
PUBCHEM
2576
Created by admin on Mon Mar 31 17:45:36 GMT 2025 , Edited by admin on Mon Mar 31 17:45:36 GMT 2025
PRIMARY
NSC
172124
Created by admin on Mon Mar 31 17:45:36 GMT 2025 , Edited by admin on Mon Mar 31 17:45:36 GMT 2025
PRIMARY
CAS
78-44-4
Created by admin on Mon Mar 31 17:45:36 GMT 2025 , Edited by admin on Mon Mar 31 17:45:36 GMT 2025
PRIMARY
DRUG CENTRAL
509
Created by admin on Mon Mar 31 17:45:36 GMT 2025 , Edited by admin on Mon Mar 31 17:45:36 GMT 2025
PRIMARY
EVMPD
SUB06631MIG
Created by admin on Mon Mar 31 17:45:36 GMT 2025 , Edited by admin on Mon Mar 31 17:45:36 GMT 2025
PRIMARY
ECHA (EC/EINECS)
201-118-7
Created by admin on Mon Mar 31 17:45:36 GMT 2025 , Edited by admin on Mon Mar 31 17:45:36 GMT 2025
PRIMARY
MERCK INDEX
m3112
Created by admin on Mon Mar 31 17:45:36 GMT 2025 , Edited by admin on Mon Mar 31 17:45:36 GMT 2025
PRIMARY Merck Index
RXCUI
2101
Created by admin on Mon Mar 31 17:45:36 GMT 2025 , Edited by admin on Mon Mar 31 17:45:36 GMT 2025
PRIMARY RxNorm
INN
902
Created by admin on Mon Mar 31 17:45:36 GMT 2025 , Edited by admin on Mon Mar 31 17:45:36 GMT 2025
PRIMARY
ChEMBL
CHEMBL1233
Created by admin on Mon Mar 31 17:45:36 GMT 2025 , Edited by admin on Mon Mar 31 17:45:36 GMT 2025
PRIMARY